Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

KIT overexpression

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

Chr t(8;21) + KIT mutation (4)

Chr t(8;21)(q22;q22) + RUNX1-RUNX1T1 fusion + KIT exon 17 mutation + CSF3R mutation (4)

Chr t(8;21)(q22;q22) + RUNX1-RUNX1T1 fusion + KIT exon 17 mutation (3)

KIT P577del + KIT W557Lfs*5 + KIT Y823D (2)

Chr inv(16)t(16;16) + KIT mutation (1)

KIT wild-type + SDHB deletion (1)

RUNX1-RUNX1T1 fusion + KIT D816 (1)

Chr t(8;21) + KIT mutation (4)

Chr t(8;21)(q22;q22) + RUNX1-RUNX1T1 fusion + KIT exon 17 mutation + CSF3R mutation (4)

Chr t(8;21)(q22;q22) + RUNX1-RUNX1T1 fusion + KIT exon 17 mutation (3)

KIT P577del + KIT W557Lfs*5 + KIT Y823D (2)

Chr inv(16)t(16;16) + KIT mutation (1)

KIT wild-type + SDHB deletion (1)

RUNX1-RUNX1T1 fusion + KIT D816 (1)

Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors (NCT00859937)

Phase 2

National Cancer Institute (NCI)

National Cancer Institute (NCI)

Completed

Phase 2

National Cancer Institute (NCI)

Completed

Last update posted :

04/20/2018

Initiation :

03/16/2009

Primary completion :

01/30/2013

KIT

|

KIT expression • KIT overexpression

|

dasatinib